| 摘要 |
This invention provides novel improved interleukin-6 (IL-6) receptor antagonists that are human IL-6 muteins having five specific mutations, and receptor-binding fragments thereof. This invention also provides pharmaceutical compositions comprising these IL-6 receptor antagonists, and methods for treating IL-6 related diseases such as sepsis and multiple myeloma by administering such pharmaceutical compositions. |
